Crystagen
EDP Tripeptide · Thymus Immune Bioregulator
Khavinson bioregulator tripeptide (EDP), identified in thymalin, acting selectively on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it raises immune function by stimulating proliferation of normal lymphocytes while holding back tumor cell growth. Research records immunity normalized in 82% of elderly patients against 56% of controls, and fewer respiratory infections in athletes, with HSP gene expression doubled.
Overview
Khavinson bioregulator tripeptide (EDP), identified in thymalin, acting selectively on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it raises immune function by stimulating proliferation of normal lymphocytes while holding back tumor cell growth. Research records immunity normalized in 82% of elderly patients against 56% of controls, and fewer respiratory infections in athletes, with HSP gene expression doubled.
Epigenetic regulation is the route: gene expression and protein synthesis in immune cells are influenced. Synthesis of heat-shock proteins and cytokines is regulated, and cell differentiation, proliferation, and apoptosis are affected. Spontaneous proliferative activity of normal lymphocytes rises under the EDP peptide, while proliferation of tumor cells (K-562 erythromyelosis) is inhibited. The B-cell immune system is activated, as are thymic epithelial cells (VTEC2.H/S).
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
The immunogram is normalized in elderly patients whose immunity is impaired.
Immune function is restored following infectious diseases.
Immunity is helped toward normal after exposure to radiation and chemotherapy.
In athletes, stress resistance increases and respiratory infections are reduced.
Expression of the heat-shock protein gene HSPA1A doubles.
K-562 cells — human erythromyelosis tumor cells — show inhibited proliferation.
- Class
- Tripeptide bioregulator
- Research status
- Moderate research
- Chain length
- 3 residues
- Molecular weight
- 359 Da
- Typical dose
- 10–20 mg daily
- Frequency
- Once daily for 10–20 consecutive days
- Cycle length
- 10–20 days per cycle
- Storage
- Capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated
Molecular data
- Type
- Tripeptide bioregulator
- Molecular weight
- 359 Da
- Chain length
- 3 residues
EDPDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard protocol | Oral capsules | 10-20 mg | Daily for 10-20 days |
| Maintenance | Oral capsules | 10 mg | 2-3 cycles yearly |
| Athletic support | Oral capsules | 10-20 mg | Daily during training cycles |
| Research protocol | IM or SubQ | 10 mg | Daily for 10 days |
Interactions
Immunoprotecting properties in both, with different mechanisms that complement.
Thymalin is the source of Crystagen (EDP); the immune effects complement.
Comprehensive Khavinson anti-aging protocols often include both.
Immune peptides that are related, and can be combined.
What to expect
Safety
Mechanistic flags — properties of the pathway, not observed adverse events.
- Tolerated well overall
- Side effects reported as minimal
- Allergic reactions
- Unusual immune symptoms
- Known hypersensitivity
- Pregnancy or breastfeeding
- Autoimmune flares that are active — consult a physician
Quality checklist
What to confirm before trusting a batch of research material. A verification aid — not an endorsement of any supplier.
- Third-party Certificate of AnalysisIndependent lab · dated · lot-matched.
- HPLC purity ≥ 98%Reverse-phase trace included.
- Mass-spec confirms 359 g/molMALDI-TOF or ESI-MS.
- Counterion stated (acetate ≫ TFA)TFA salts can confound bioassays.
- Endotoxin / sterility statementRelevant once reconstituted.
- Lyophilised · cold-chain shippedStored −20 °C, shipped on ice.
- Labelled “research use only”No therapeutic or dosing claims.
Recorded signals for this compound · 7
- ✓White powder or capsules
- ✓If reconstituted, a clear solution
- ✓Packaging and labeling done properly
- !Source or purity unknown
- ×Discoloration
- ×Unusual odor
- ×Damaged packaging
FAQ
Does Crystagen reduce respiratory infections in athletes?
Yes. In research, HSP gene expression in athletes doubled and respiratory infections fell across the study population. Heat-shock protein production is enhanced and IL-6 expression normalized, which strengthens immune resilience under heavy training stress, when illness risk runs high.
In what share of elderly patients does immune function improve with Crystagen?
Clinical research put normalization of immune function (immunogram) at 82% of elderly patients, against only 56% in the control group. A difference that size suggests age-related immune decline is effectively reversed, though individual results vary.
Is Crystagen safe where an active autoimmune condition is present?
As an immune-stimulating peptide it may worsen active autoimmune flares, since lymphocyte proliferation and immune activation are both enhanced. Medical consultation before use is essential, and more so during a flare of autoimmune disease. Immunodeficiency is the better-suited setting, not autoimmunity.
Does Crystagen protect immune function after chemotherapy?
Yes. Effectiveness at normalizing immunity after chemotherapy and radiation exposure is shown in research. Being a thymus-derived immune bioregulator, it supports the recovery of lymphocyte populations and of immune surveillance, both suppressed by cancer treatments.